TMCnet News
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context. The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted to a new employee on their hire date (June 8, 2026) with an exercise price equal to the closing price of Context’s common stock as reported by Nasdaq on the grant date ($1.71 per share). The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments hereafter. Vesting of the stock options is subject to continued service with Context through the applicable vesting date. About Context Therapeutics® Investor Relations Contact: 
|
